Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection
Status:
Terminated
Trial end date:
2002-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs such as vapreotide may prevent complications following pancreatic resection.
It is not yet known if vapreotide is more effective than no further therapy in preventing
side effects of pancreatic resection.
PURPOSE: This randomized phase III trial is studying vapreotide to see how well it works
compared to a placebo in preventing complications in patients undergoing surgery for
pancreatic cancer.